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Abstract
Screening for fetal aneuploidy in pregnant women using cell-free DNA has increased dramatically 
since the technology became commercially available in 2011. Since that time, numerous trials 
have demonstrated high sensitivity and specificity to screen for common aneuploidies in high-risk 
populations. Studies assessing the performance of these tests in low-risk populations have also 
demonstrated improved detection rates compared with traditional, serum-based screening 
strategies. Concurrent with the increased use of this technology has been a decrease in invasive 
procedures (amniocentesis and chorionic villus sampling). As the technology becomes more 
widely understood, available, and utilized, challenges regarding its clinical implementation have 
become apparent. Some of these challenges include test failures, false-positive and false-negative 
results, limitations in positive predictive value in low-prevalence populations, and potential 
maternal health implications of abnormal results. In addition, commercial laboratories are 
expanding screening beyond common aneuploidies to include microdeletion screening and whole 
genome screening. This review article is intended to provide the practicing obstetrician with a 
summary of the complexities of cell-free DNA screening and the challenges of implementing it in 
the clinical setting.
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Learning Objectives—After completing this activity, the learner should be better able to 
understand the complexities of cell-free DNA screening and describe considerations involved in its 
clinical implementation.
The American Congress of Obstetricians and Gynecologists (ACOG) recommends that all 
pregnant women, regardless of age, be offered aneuploidy screening before 20 weeks' 
gestation.1 Before the development of first and second trimester screening tests, a woman's 
age and pregnancy history were the only means by which a provider could stratify a patient's 
risk for Down syndrome. Serum screening for Down syndrome became available in the 
1980s, and since that time numerous screening options have evolved using a combination of 
serum analytes including alpha-fetoprotein, human chorionic gonadotropin, unconjugated 
estriol, inhibin A, and pregnancy-associated plasma protein A (PAPP-A), as well as 
ultrasound markers (such as first trimester nuchal translucency and presence or absence of 
nasal bone and second trimester markers such as an increased nuchal fold). In addition, 
screening has now expanded beyond Down syndrome to include trisomies 13 and 18.
Combinations of serum screening approaches and ultrasound have yielded the triple, quad, 
and penta screens; the first trimester combined test; the integrated screening test; and the 
sequential screening test (both stepwise and contingent). Invasive testing for aneuploidy, in 
the form of chorionic villus sampling or amniocentesis, has traditionally been offered to 
women who will be at least 35 years old at delivery or who have other risk factors for 
aneuploidy. However, practice has changed to make invasive diagnostic testing available to 
all pregnant women, regardless of age or other risk factors for aneuploidy.2 This change is 
the result of an increased appreciation for the importance of patient preferences in decision 
making surrounding prenatal screening and diagnostic testing coupled with low loss rates 
from invasive diagnostic procedures and the ability to comprehensively screen for 
chromosome abnormalities and other genetic syndromes with microarray. As screening has 
evolved, the goal has been to maximize detection rate while minimizing the false-positive 
rate.
Discovery of Cell-Free DNA in Pregnancy
In 1997, researchers identified what they described as cell-free “fetal DNA” in maternal 
circulation by identifying Y-specific DNA fragments in serum and plasma samples collected 
from pregnant patients.3 The following year, efforts to quantify the amount of cell-free DNA 
(cfDNA) from the pregnancy present in maternal serum using real-time polymerase chain 
reaction showed that it represented 3.4% to 6.2% of the total cfDNA in maternal plasma.4 
Subsequent studies have shown that the percentage may be as high as 10% to 20%.5 Once 
the presence of cfDNA from a pregnancy was identified and quantified, it was immediately 
identified as a potential source of material for prenatal aneuploidy screening. In 1999, the 
first report that pregnancies with trisomy 21 had higher concentrations of circulating cell-
free “fetal DNA” compared with those with euploid fetuses was published.6 Thus began the 
race for laboratories to develop the technology to identify, quantify, and sequence cfDNA in 
pregnancies to screen for aneuploidy and other genetic conditions.
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Technology
Cell-free DNA from a pregnancy is thought to come from apoptotic trophoblastic cells and 
is thus placental in origin. Some researchers have dropped the term “fetal” from current 
descriptions of the technology to reflect this understanding. Cell-free DNA circulates as very 
small fragments (less than 200 base pairs), is detectable in maternal serum as early as 7 
weeks' gestation, and is rapidly cleared after delivery.7,8 Numerous terms have been used to 
describe these tests, including noninvasive prenatal testing, noninvasive prenatal screening, 
noninvasive prenatal diagnosis, and cfDNA screening.
The first commercial screening test for aneuploidy using cfDNA became available to 
patients and providers in 2011. Since then, other platforms have become available, and now 
patients and providers may choose from several different commercial tests sold by various 
laboratories. Each of the platforms that provide these tests uses different applications of 
next-generation sequencing technologies. The first described technique was massively 
parallel shotgun sequencing, which refers to technology that counts and sequences millions 
of fragments of DNA in plasma, thereby yielding tens of millions of short sequence reads. 
The laboratory then maps these short sequences to the chromosome of origin.9 If there is 
excess DNA present from the chromosome of interest (ie, chromosome 21), this result is 
consistent with aneuploidy for that chromosome. The approach is described as “shotgun” 
because all chromosomes are sequenced and mapped. A similar but alternative platform 
amplifies, sequences, and maps fragments from targeted chromosomes (eg, 13, 18, 21, and 
sex chromosomes).10 This approach is called targeted massively parallel sequencing. 
Because massively parallel shotgun sequencing and targeted massively parallel sequencing 
compare actual to expected amounts of DNA, these techniques are not able to make a 
distinction between maternal and placental cfDNA. Alternatively, a third approach uses 
differences in single-nucleotide polymorphisms (SNPs) between maternal and placental 
DNA to determine risk for aneuploidy by performing targeted amplification and analysis of 
thousands of SNPs on chromosomes 21, 18, 13, X, and Y.11
Uptake and Impact on Invasive Procedures
Since its introduction to clinical practice, cfDNA screening for aneuploidy has seen 
extraordinary uptake among high-risk patients in the United States. 12–14 This has been 
observed among obstetricians and maternal fetal medicine specialists alike.15 Regional 
differences in uptake in the United States have been documented with 1 study showing less 
frequent cfDNA screening in the Midwest compared with the East and West coasts.16 The 
rapid application of cfDNA screening for aneuploidy has also been seen globally.17–19
Concurrent with the introduction of cfDNA screening in clinical practice has been a 
documented decrease in invasive procedures. Even before cfDNA screening was widely 
available, decision-analytic models predicted a decrease in both invasive procedures and 
pregnancy loss related to this testing. One model predicted that cfDNA screening would 
decrease invasive procedures in high-risk pregnancies by more than 95% and reduce euploid 
pregnancy loss rates by more than 99%.20 Subsequent studies investigating these predictions 
confirmed these estimates. One large, retrospective study of more than 15,000 procedures 
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performed over 9 years at 1 hospital in the United States demonstrated a decrease in 
amniocentesis (76%) and chorionic villus sampling (54%) after the introduction of cfDNA 
screening in 2012.21 Numerous other studies have confirmed a decrease in the number of 
invasive procedures that prenatal diagnosis centers are now performing.22
Professional Society Guidelines
Since 2011, numerous professional societies have published guidelines for the use of cfDNA 
screening in pregnancy, including ACOG, the Society for Maternal Fetal Medicine (SMFM), 
the National Society for Genetic Counselors, the International Society for Prenatal 
Diagnosis (ISPD), and the American College of Medical Genetics and Genomics. Initial 
guidelines from all major societies recommended limiting the use of cfDNA screening to 
only those pregnancies at increased risk of aneuploidy. Increased risk was typically defined 
as age 35 years or older at the time of delivery, ultrasound findings that suggest an increased 
risk of aneuploidy, positive first or second trimester screening tests for aneuploidy, a history 
of a previous pregnancy with trisomy, or a parental balanced Robertsonian translocation that 
increases the risk of trisomy 21 or 13.23 As more research became available validating the 
performance of cfDNA screening in general obstetric populations, some societies softened 
previous recommendations to limit cfDNA screening to high-risk patient populations. In a 
2012 Committee Opinion, ACOG recommended that cfDNA not be offered to low-risk 
women or women with multiple gestations.23 In September 2015, a joint ACOG/SMFM 
Committee Opinion was published that stated “given the performance of traditional 
screening methods and the limitations of cfDNA, conventional screening methods remain 
the most appropriate choice for first-line screening for most women in the general obstetric 
population.” ACOG and SMFM, however, acknowledged that patients may choose cfDNA 
screening regardless of their risk status, and in those cases, the limitations and benefits of 
this screening strategy should be discussed in the context of alternative screening and 
diagnostic options. ACOG and SMFM continue to recommend that patients should receive 
pretest counseling to discuss the risks and benefits of screening, that diagnostic testing be 
recommended to patients who receive a positive cfDNA screening result, and that pregnancy 
management decisions, including termination, should not be made based upon a cfDNA 
screen result alone.24
Earlier in 2015, ISPD updated its position statement on chromosome abnormality screening. 
Previously, the society recommended that cfDNA screening be limited to women at 
increased risk for aneuploidy only. In their updated guidelines, however, ISPD listed many 
different screening protocols that they consider appropriate including the use of cfDNA 
screening as a primary test offered to all pregnant women, or the use of cfDNA screening in 
combination with numerous other screening strategies.25
While some laboratories will report results on cfDNA screening tests performed on twin 
pregnancies, ACOG and SMFM do not recommend the use of cfDNA screening in multiple 
gestations. Instead, these organizations acknowledge that preliminary studies suggest that 
this form of screening is accurate but await the results of larger prospective studies before 
changing this recommendation.24 ISPD states that if a cfDNA test is interpretable, 
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performance in a twin pregnancy is expected to be equivalent to that for singletons, but does 
not provide specific guidelines for or against the use of cfDNA in twin pregnancies.25
Performance of cfDNA Screening Tests
Validation studies published soon after cfDNA became widely available demonstrated high 
sensitivity and specificity to screen for aneuploidies in high-risk populations regardless of 
the technology or the platform studied.10,11,26,27 This was especially true for trisomies 21 
and 18. When comparing cfDNA screening tests in high-risk populations to other prenatal 
screening options, cfDNA screening has been shown to have higher detection rates and 
lower false-positive rates and can be performed at an earlier gestational age (Table 1). In 
subsequent studies investigating clinical performance in low-risk or general obstetrical 
populations, cfDNA screening continued to show higher sensitivity and specificity when 
compared with other screening tests.12,32–34
A recent meta-analysis of 37 studies in both high-risk and general-risk populations 
investigating cfDNA screening for aneuploidy found a pooled weighted detection rate (DR) 
for trisomy 21 of 99.2%, for trisomy 18 of 96.3%, and for trisomy 13 of 91.0%.28 It is worth 
noting that for most validation and clinical studies, cases with mosaicism (potentially 
leading to a false-positive result), complex karyotypes, and samples with a low fetal fraction 
were excluded. This has the potential to overstate the detection rates and minimize the false-
positive rates. The concept and implications of low fetal fraction will be described later in 
this review.
Overall, despite differences in the technology that is used, performance among the available 
platforms in clinical trials is similar, and as such, 1 platform is not recommended over 
another based upon peer-reviewed and published performance data.
Complexities and Challenges Of Clinical Implementation
Cost
One of the central tenets of medical screening is cost-effectiveness.35 The cost of cfDNA 
screening can be one of the largest challenges of widespread clinical use. In the United 
States, the cost of the various cfDNA screening tests remains high, ranging from 
approximately $700 to over $2700.36,37 Actual cost to the patient is a function of the 
laboratory used, the conditions screened for, whether or not the patient has insurance, and if 
she has insurance, the extent to which her insurance company reimburses the cost of the test.
While the actual costs to patients may not be high, widespread use at current prices have 
significant implications on the population level. Several researchers have performed 
decision-analytic and cost-effective modeling studies to investigate the economic impact of 
using cfDNA screening alongside or instead of traditional screening methods. These studies 
are challenging because the value of cfDNA screening must be considered from different 
standpoints (ie, patient, payer, governmental, or societal). In addition, the cost of cfDNA 
screening must be compared with the cost of several different serum screening 
strategies.38–43 A recent economic decision analysis compared conventional screening to 
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cfDNA screening in a theoretical cohort of pregnant women in the United States and found 
that replacing conventional screening with cfDNA screening would reduce health care costs 
if the test could be provided for $744 or less in the general pregnancy population. Further, in 
this model, cfDNA had a higher detection rate compared with conventional screening 
(96.52% vs 85.9%), reduced the theoretical number of invasive procedures by 60%, and 
reduced the number of theoretical procedure-related euploid pregnancy losses by 73.5%.38
Notably, most studies investigating the cost-effectiveness of cfDNA screening have been 
performed by, or in association with, commercial laboratories. These studies are often 
limited in that they do not consider all potential outcomes of a prenatal screening or 
diagnostic testing strategy (eg, a failed test, an anomaly that would have been detected by 
another method of screening, or a chromosomal finding for which there is no current 
cfDNA-based screening). In 1 study, when a comprehensive set of outcomes was considered 
using 6 different testing strategies (diagnostic testing with chromosomal microarray, 
multiple marker screening, cfDNA screening, and nuchal translucency screening alone, in 
combination, or in sequence), the authors found that multiple marker screening with the 
option of diagnostic testing for screen-positive results was the optimal strategy for most 
women. In addition, they concluded that it is not until age 40 years that cfDNA screening 
became optimal and cost-effective as a primary screening test.44 While the cost associated 
with cfDNA screening may not be prohibitive to an individual patient, the aggregate costs of 
using this technology will continue to influence public health, governmental agencies, and 
private payers.
Interpreting Results
One challenge in interpreting results of cfDNA screening test is the amount of variability in 
how results are reported to patients and providers. First, laboratories are not consistent with 
the language used to communicate results. Examples of screen-positive results include 
“positive,” “high risk,” “aneuploidy detected,” and “aneuploidy suspected.” Similar 
language is often used for negative results. Often, this language is paired with a numeric 
probability (often greater than 99/100 [99%]), which is reflective of the laboratory's 
confidence that the result is abnormal rather than the odds that the pregnancy is affected 
given the abnormal result. If a laboratory reports a “positive” result for trisomy 21 paired 
with a sensitivity and specificity of 99%, and a “probability” of 99/100, it is plausible that a 
patient or provider may interpret this result as nearly diagnostic. To appropriately interpret 
the results of a screening test, however, it is important to understand the relationship 
between a test's sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) (Table 2). In this setting, a test's sensitivity (or detection rate) is the 
number of affected pregnancies identified by the test divided by the total amount of affected 
pregnancies. The specificity of a test is the number of unaffected pregnancies identified by 
the test divided by the actual number of unaffected pregnancies. Neither the sensitivity nor 
the specificity of a test is affected by disease prevalence. Sensitivity and specificity are 
population measures that look backwards at results gathered over time and are of less use to 
clinicians and patients than the indices that assess the test's ability to accurately predict an 
actual result. The PPV and NPV of a test are of more use in the clinical setting as they are 
individual measures that are forward-looking.35 The PPV, or the likelihood that a pregnancy 
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is affected if the test is positive, is a function of disease prevalence. Laboratories who 
perform cfDNA screening tests often tout their tests' sensitivity and specificity in direct-to-
patient and direct-to-provider marketing as a measure of accuracy. False-negative and false-
positive cfDNA screening results have been reported despite very high sensitivity and 
specificity.45,46 ACOG and SMFM have encouraged laboratories to report both PPV and 
residual risk (the risk that a patient may have an affected pregnancy despite a negative test) 
on their reports but most laboratories do not currently report this information.24 A positive 
result with a low, but undisclosed, PPV may be misinterpreted as diagnostic by some 
patients or providers. There is evidence that up to 6% of women who received positive 
cfDNA screening results proceeded with pregnancy termination without confirming 
results.32
A woman's a priori risk for aneuploidy, as determined by her age or other risk factors, is an 
important consideration when interpreting screening tests for aneuploidy. Screening 
performed in low-risk women will have a lower PPV than the same screening test performed 
in a high-risk woman. Because a priori risk affects the PPV of cfDNA and laboratories are 
inconsistent with reporting the PPV on reports, 2 Web-based calculators have been made 
available to estimate the PPV of cfDNA screening to assist providers in interpreting results 
and to enhance patient counseling.47,48 The calculator developed by the Perinatal Quality 
Foundation can be found at https://www.perinatalquality.org/Vendors/NSGC/NIPT/. The 
calculator developed by the University of North Carolina Department of Obstetrics and 
Gynecology can be found at: http://www.mombaby.org/NIPS. Until laboratories consistently 
report PPV and residual risk, tools such as these will continue to be important assets to 
providers and genetic counselors who interpret and communicate results to patients.
Fetal Fraction
Fetal fraction, or the proportion of circulating cfDNA that is from the fetoplacental unit, is 
the single most important factor that determines the reliability of a cfDNA screening 
result.49 Some laboratories measure and report fetal fraction and require at least 4% to report 
a result. A low fetal fraction is the most common reason for a screen failure and occurs from 
1% to 8% of the time, depending on the platform and laboratory used.24 Fetal fraction is 
known to be affected by gestational age, maternal weight, and the presence of 
aneuploidy.50,51 Obesity is associated with increasing total cfDNA, which is thought to be 
from increased apoptosis of adipocytes. Because fetal fraction is the percent of cell-free fetal 
DNA divided by maternal cfDNA, the overabundance of total cfDNA in obese pregnant 
women results in lower relative amounts of cfDNA from the fetus and the placenta and may 
increase the risk of a test failure.52 In a nested case-control study of almost 400 pregnancies 
that had cfDNA screening between 11 and 13 weeks gestation, increasing maternal weight 
from 60 to 120 kg decreased the mean fetal fraction from 12% to 6%. Among women who 
weigh more than 250 lb, 10% may have a fetal fraction of less than 4%.53
Another common cause for a screen failure due to low fetal fraction is the presence of a 
pregnancy affected by aneuploidy. Studies have reported an increased fetal fraction in a 
pregnancy affected by trisomy 21.54,55 However, studies have reported a significantly 
decreased fetal fraction in pregnancy affected by trisomy 18, trisomy 13, monosomy X, and 
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triploidy 50 Some laboratories recommend repeating the cfDNA screen at a later gestational 
age after an initial failure. However, the rate of repeat test failure may be as high as 40% to 
50%, and the rate of aneuploidy has been reported to be significantly higher (odds ratio, 9.2; 
confidence interval, 4.4–19.0) among women who receive an uninterpretable result from 
cfDNA screening.24,33 For this reason, ACOG and SMFM suggest that women who receive 
an inconclusive or uninterpretable result should receive additional genetic counseling and be 
offered ultrasound screening and diagnostic testing. If the patient elects for repeat cfDNA 
screening, the increased risk for aneuploidy and the risk of a repeat test failure should be 
disclosed and discussed.
False-Positive Results
Discordancy (false-positive or false-negative) between cfDNA screening tests and true fetal 
karyotypes have been reported and remain an important consideration when utilizing cfDNA 
screening for aneuploidy. The actual frequency of discordant results in clinical practice is 
unknown. Laboratories do not routinely request that discordant results be reported to them 
and there is no central registry for reports of false-positive or false-negative results.45 
Despite this, numerous causes of discordant results have been reported. The following are 
some of the more commonly reported reasons for a discordant or false-positive result:
Placental Mosaicism—As previously discussed, the primary source of cfDNA is 
trophoblastic tissue. The chromosome complement of the placenta may not be the same as 
that of the fetus. This phenomenon is known as confined placental mosaicism and is a 
common reason for a cfDNA screening tests to yield a false-positive result.
Demise of Co-Twin—Another cause for an abnormal cfDNA screen in an unaffected 
singleton pregnancy is the presence of a demised co-twin, often described as a “vanishing 
twin.”56 When products of conception are successfully karyotyped, approximately half have 
a chromosomal abnormality57. In 1 study, 15% of false-positive screen results were the 
result of a demised co-twin.58 There are no formal guidelines to indicate how long after the 
demise of a co-twin cfDNA remains present from the co-twin. Therefore, cfDNA screening 
is contraindicated in this setting. If fact, some providers who routinely use cfDNA screening 
recommend or require that an ultrasound be performed at the time of cfDNA screening to 
rule out a demised co-twin or spontaneous abortion to minimize the risk of a discordant 
result or reporting a result on a nonviable pregnancy.
Maternal Karyotype Abnormality—Another important cause of discordant results of 
cfDNA screening is abnormal maternal chromosome complement. Previously unknown 
maternal mosaicism (low-level maternal Turner syndrome, for example) may yield a positive 
screen for sex aneuploidy in an unaffected pregnancy.59,60 Maternal copy-number variations 
are other potential sources of discordant results.61 Copy-number variants are structural 
alterations in a chromosome as a result of a duplication or deletion. Because most cfDNA is 
maternally derived, if a woman carries a previously unknown deletion or duplication on a 
targeted chromosome, it is plausible that some cfDNA platforms may interpret this 
underrepresentation or overrepresentation as fetal aneuploidy or a fetal microdeletion or 
duplication.
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Maternal Malignancy—Another source of a positive cfDNA screen in an unaffected 
pregnancy is the presence of a maternal malignancy. The first report of a discordant cfDNA 
screening test and a subsequently diagnosed maternal malignancy was published in 2013. In 
this case, the patient's cfDNA screen returned positive for fetal trisomy 13 and monosomy 
18. The patient elected for an amniocentesis, and karyotype and microarray were consistent 
with a normal male fetus (46,XY). The patient was subsequently diagnosed with a metastatic 
neuroendocrine carcinoma in the postpartum period.62 After this case report, occult maternal 
malignancy became part of the differential diagnosis for discordant cfDNA screening results. 
Since then, a case series of 10 cases of patients with cancers diagnosed after discordant 
cfDNA screening has been published.63 Seven of the 10 cases reported in this series had 
cfDNA results indicative of multiple aneuploidies detected, and 1 of the 10 had results 
consistent with a nonviable monosomy. It is presumed that the source of the abnormal 
cfDNA is the cytogenetic abnormalities in the tumor cells. In addition to the previously 
described neuroendocrine carcinoma (that was included in this case series), other occult 
malignancies included 3 cases of non-Hodgkin lymphoma, an acute T-cell lymphoblastic 
leukemia, anal cancer, and colorectal cancer. Using their data, the authors of this series 
estimated that there is between a 20% and 44% risk of maternal cancer if multiple 
aneuploidies are detected using cfDNA screening. These data need to be confirmed by 
additional studies before recommendations can be made about how to evaluate a cfDNA test 
that is positive for multiple aneuploidies.
Maternal Health Implications
As discussed previously, it is clear that cfDNA screening has the potential to discover 
previously unknown conditions in a pregnant woman. Some of these conditions may have no 
clinical significance or may have uncertain clinical significance. Other conditions, as in the 
case of an occult malignancy, have significant medical implications for a woman. The 
potential maternal health implications of cfDNA screening for aneuploidy continue to be 
researched and debated. However, there are as yet no guidelines for laboratories or providers 
regarding how incidental maternal health implications of cfDNA should be reported and 
what evaluation and follow-up is appropriate. In the interim, providers must be aware of the 
maternal health implications of cfDNA screening and must decide to what extent these 
possibilities should be addressed during pretest counseling.
Comparison to First Trimester Screening
It is important to remember that cfDNA screening does not screen for every possible 
chromosomal abnormality. Cell-free DNA screening is highly sensitive and specific in 
screening for trisomies 21 and 18, and to a lesser extent trisomy 13. However, a large 
retrospective cohort study of over 450,000 women in California participating in a state-wide 
prenatal screening program who received first trimester screening, second trimester 
screening, or both in an integrated risk assessment demonstrated that the program achieved 
high detection rates for trisomy 21 of 92%, for trisomy 18 of 93.2%, and for trisomy 13 of 
80.4% while also detecting 80% of all chromosome abnormalities (including other trisomies, 
monosomy, translocations, additions, duplications, inversions, rings, polyploidy, triploidy, 
and other chromosome abnormalities).64 Another study evaluated how many chromosome 
abnormalities were detected by diagnostic testing as compared with cfDNA screening 
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among women who were identified as screen-positive by traditional screening. Over 1.3 
million patients were screened in a state-wide screening program, and 68,990 (5.2%) were 
screen-positive. Of the chromosome abnormalities detected among these screen-positive 
women, 83.1% had a chromosome abnormality that was predicted to be detectable with 
current cfDNA screening methods, whereas 16.9% had a chromosome abnormality 
considered not currently detectable.65 Both of these studies underscore the fact that current 
cfDNA screening tests do not detect all chromosome abnormalities, some of which may be 
detected by conventional screening followed by invasive testing.
Screening Beyond Common Aneuploidies
Sex Chromosome Aneuploidy—Soon after the rapid adoption of cfDNA screening in 
high-risk populations, laboratories began investigating and reporting the expansion of the 
technology to screening for conditions beyond common aneuploidies. Cell-free DNA 
screening has remarkably high detection rates for fetal sex with 1 meta-analysis reporting a 
sensitivity of 94.4% and a specificity of 98.6% for detecting Y chromosome sequences 
among women pregnant with a male fetus.66 Laboratories who report fetal sex chromosome 
complement now often report fetal sex chromosome aneuploidy (SCA), when suspected. 
Consequently, patients who may be motivated to pursue cfDNA screening for autosomal 
aneuploidies or for the purposes of determining fetal sex may also receive simultaneous 
SCA screening. The most common SCAs are 47,XXX, 47,XXY, 47,XYY, and 45,X and 
have a combined incidence of 1/350 to 1/400 live births.67 Ultimately, clinical performance 
of cfDNA screening tests to detect SCAs in large populations is unknown. Most data 
regarding clinical performance centers on the sensitivity to detect nonmosaic monosomy X 
(45,X). Four published studies report detection rates for monosomy X ranging from 75% to 
92%.26,68–70 Robust performance data for the less common SCAs are not yet available.
The phenotypes of people with SCA are highly variable. Most people with SCAs other than 
45,X have few serious physical abnormalities, especially when compared with autosomal 
trisomies. This makes prenatal counseling and decision making complex when a cfDNA 
screening test returns positive for an SCA. Further complicating this counseling is the fact 
that maternal mosaicism for an SCA may result in a false-positive cfDNA pregnancy screen.
Microdeletion Syndromes—In addition to autosomal and SCA, laboratories have 
expanded screening to include various microdeletion syndromes. Microdeletions are small 
deletions (<5 Mb) that often span several genes and are typically too small to be detected by 
traditional or high-resolution karyo-types. They differ from autosomal aneuploidies in 2 key 
ways: they are not related to maternal age, and individually, they are far less common than 
autosomal or sex aneuploidies. Expanded screening panels offered by some laboratories 
include screens for 22q11 deletion syndrome, cri-du-chat (5p-), Wolf-Hirschhorn syndrome 
(4p-), Prader Willi or Angelman syndrome, 11q deletion (Jacobsen syndrome), 8q deletion 
(Langer-Giedion syndrome), 1p36 deletion syndrome, and some rare trisomies often 
associated with nonviable pregnancies (trisomies 16 and 22). 22q11 deletion syndrome is the 
most common of the microdeletion syndromes screened by current expanded panels, with a 
prevalence of 1:4000 to 1:6000.71 Other microdeletion syndromes have even lower 
prevalence. Cru-di-chat syndrome, for example, is estimated to be present in 1 in 50,000 live 
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births.72 Screening for conditions with such low prevalence will inevitably result in false-
positive results as the PPV will be low. One recent study investigating SNP-based methods 
to detect microdeletion syndromes found PPVs that ranged from 3.8% to 17%, depending on 
the syndrome.73 When some laboratories began offering expanding microdeletion panels, 
they did so in an “opt-out” manner. Similar to SCAs, data on the clinical performance of 
cfDNA screening tests for microdeletion syndromes in large populations are not available. 
Due to lack of clinical data, ACOG and SMFM recommend against routine use of cfDNA 
screening for microdeletion syndromes.24
Whole Genome Screening—Thus far, expansion of cfDNA screening has been largely 
driven by clinical laboratories and the scope of this screening continues to expand. One of 
the cfDNA platforms is now offering clinical testing with whole genome screening and 
reporting any aneuploidy, select microdeletions, and any chromosomal gains or losses 
greater than 7 Mb. This is roughly on par with the resolution of a karyotype and does not 
provide the same resolution as a chromosomal microarray analysis.74 Data demonstrating 
actual clinical performance of this test have not been published, and guidelines regarding its 
use in clinical practice have not been issued.
Ethical, Legal, and Social Considerations
Beyond the challenges of clinical implementation, the rapid update of prenatal cfDNA 
screening has raised numerous ethical and legal considerations. An early concern of 
noninvasive prenatal screening was that of burdening women with decision-making 
regarding results of cfDNA screening tests performed on early pregnancies that are destined 
to miscarry.75 The fact that cfDNA screening can be carried out at a gestational age earlier 
than conventional screening may be a benefit to some but a liability to others. In addition, as 
the cost of cfDNA screening goes down, some have questioned whether the safety and 
accuracy of cfDNA screening may shift it from an option involving a patient's preferences 
and informed consent to a routine procedure included in initial prenatal laboratories.76 This 
would represent a dramatic shift in the prenatal screening paradigm from one that was 
traditionally performed in targeted populations. If it is to remain a procedure that a well-
informed woman can accept or reject, consideration must also be given to how the process of 
obtaining informed consent should evolve alongside the ever-increasing number of 
conditions that laboratories screen for using cfDNA; each with their own prevalence, 
detection rate, and PPV. Ethical and legal concerns increase substantially when 
consideration is given to the potential that cfDNA offers in the near future—from testing for 
disease predisposition (ie, breast cancer), to paternity, to late-onset conditions (ie, 
Huntington disease), to sequencing of the whole fetal genome. Some have questioned 
whether or not prenatal screening or testing for more minor conditions may trigger or 
exacerbate belief in “genetic determinism”: the belief that a person's genes determine their 
capacity and characteristics beyond that of environmental influences (social environment 
and upbringing).77 Potential expansion of the technology to broad-scope screening 
(phenotypically mild conditions, variants of unknown significance, genetic predisposition 
for certain diseases, or susceptibilities for behavioral characteristics) has caused others to 
question the benefit-to-harm ratio for the child.78 On one hand, there may be benefit to 
diagnosing a condition that may have otherwise gone unnoticed over the course of a child's 
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lifetime because the child may receive improved care. On the other hand, a child's future 
autonomy may be undermined by no longer making it possible for them to “not know.”79 In 
addition, the child may be subjected to harm in the form of diminished self-esteem, parental 
overprotectiveness, and stigmatization.78
Another ethical concern of wide-spread use of cfDNA screening is that of utilizing the 
technology for the purposes of sex selection. Globally, sex selection and sex-selection 
abortion almost always results in the abortion of female fetuses.80 Given the accuracy that 
cfDNA screening offers for detecting fetal sex at an early gestational age, the concern that 
this technology may be used solely for the purposes of sex selection seems well-founded.
Summary
The use of cfDNA in maternal blood for prenatal screening is rapidly evolving. Soon after 
this technology became available for clinical use, it expanded beyond screening for trisomy 
21 to include screening for trisomy 18, trisomy 13, and fetal sex. Recently, commercial 
laboratories have begun to offer expanded cfDNA screening options that include sex 
aneuploidies, microdeletion syndromes, and even whole genome sequencing. While 
detection rates for common aneuploidies are high in clinical trials and the use of invasive 
testing had decreased since these screening tests became available, there continue to be 
clinical challenges and complexities that make the use of these tests in all women, for all 
conditions offered, anything but routine. Clinicians who elect to offer prenatal screening 
using cfDNA should be familiar with the performance of the test used, the role that a 
patient's age (or other risk factors for aneuploidy) may play in the test's performance, the 
conditions being screened for, the manner in which results are reported, and how to interpret 
results to patients. Thorough pretest and posttest counseling to discuss the risks and benefits 
to screening should be provided to patients who elect for cfDNA screening. Clinicians and 
counselors should have an understanding of the common reasons for false-positive and false-
negative results and should offer patients confirmatory testing in the event of a positive 
screen. Providers should be familiar with society guidelines that provide guidance regarding 
the use of cfDNA screening in women at low-risk for aneuploidy and women with multiple 
gestations. Finally, physicians and genetic counselors should be familiar with the ethical and 
social considerations that are being raised as the use of this technology quickly moves 
beyond screening for common aneuploidies within the confines of clinical trials to wide-
spread commercial use driven by industry.
Practical Pearls
• Cell-free DNA screening has a much higher detection rate for trisomy 21 than 
traditional, serum-based first or second trimester screening. Performance for 
trisomies 13 and 18 is somewhat less robust.
• Patients should receive pretest counseling detailing the risks, benefits, and 
alternatives to cfDNA screening. In addition, they should receive post-test 
counseling regarding the meaning of their results and the limitations of the test.
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• Laboratories present positive and negative results of cfDNA screening in 
multiple different ways, and providers should be familiar with the meaning and 
implications of their laboratory's report.
• PPV is a function of disease prevalence. The probability that a positive result is a 
true positive is influenced by a patient's prior risk. A patient's age and other risk 
factors for aneuploidy should be taken into consideration when interpreting a 
positive result.
• An uninterpretable or inconclusive result increases a patient's risk for aneuploidy, 
and these patients should be offered comprehensive ultrasound and diagnostic 
testing.
• Positive screening results should be confirmed with diagnostic testing.
• cfDNA screening does not test for all genetic conditions, and a negative result 
does not ensure a pregnancy is unaffected.
• There is limited evidence for the clinical performance of cfDNA screening for 
microdeletion syndromes, and the routine use of cfDNA to screen for these 
conditions is not currently recommended.
• There are no peer-reviewed data available on whole genome screening using 
cfDNA.
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Table 1
Comparison of Prenatal Screening Options1,28–31
cfDNA Screening First Trimester Screening
Second Trimester 
Screening (Quad 
Screen)
Integrated Screen (NT, PAPP-A, Quad 
Screen)
Gestational age >10 wk 11–14 wk 15–24 wk PAPP-A: 9–13 wk
NT: 10–13 wk
Quad screen: 15–24 wk
Detection rate
 Trisomy 21 99.2 82–87 81 94–96*
 Trisomy 18 96.3 81 60 90†
 Trisomy 13 91.0 Limited data N/A Limited data
*
Detection rate for trisomy 21 of a fully integrated screen that includes a nuchal translucency measurement.
†
Detection rate of trisomy 18 of a serum integrated screen.
NT indicates nuchal translucency; N/A, not applicable.
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Table 2
Important Screening Tests Indices
Sensitivity Probability that a screening test will be positive if pregnancy is affected
Specificity Probability that the screening test will be negative if pregnancy is unaffected
PPV* The probability that a pregnancy is affected if the test is positive
NPV* The probability that a pregnancy is unaffected if the test is negative
*
Both PPV and NPV are dependent upon the disease prevalence or a priori risk.
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